Sells spinal implants, surgical access and monitoring systems, and imaging equipment to hospitals and surgical centers for spine procedures.
10-K for FY2025, filed Feb 24, 2026The following is a description of the primary components of our revenue and expenses:View ↗
We have differentiated surgical access instruments that are designed to maximize patient outcomes through enhanced visibility and rigidity…View ↗
Our SafeOp Neural InformatiX System was the first reflection of the IX product platform. SafeOp is a patented technology that delivers…View ↗
Our EOS imaging system is designed to provide unbiased, high-quality, and calibrated full-body imaging that enables a 3D model of patients’…View ↗
The company invoices hospitals and surgical centers for products; implant and equipment sales are tied to shipment, delivery, or surgical use, while imaging service sales are tied to services performed. Payment terms vary and follow customary business practices.
10-K for FY2025, filed Feb 24, 2026We market and sell our products through a sales force consisting of exclusive independent sales agents and dedicated employee direct sales…View ↗
Sales are derived primarily from the sale of spinal implant products, imaging equipment, and related services to hospitals and medical…View ↗
Revenue. We derive our revenue primarily from the sale of spinal surgery implants used in the treatment of spine disorders, as well as from…View ↗
$764.2M
10-K for FY2025, filed Feb 24, 2026
$764.2M ↗
Hospitals and surgical centers are the primary customers. The company sells through exclusive independent sales agents and employee sales representatives; U.S. surgeons typically decide which products are used, and hospitals are generally invoiced.
10-K for FY2025, filed Feb 24, 2026
Not on paper. It lost $143.4M in FY2025, but brought in more cash than it spent: $2.8M of free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
−$5.5MView ↗
8-K, filed Aug 4, 2026
The Company now expects adjusted EBITDA of approximately $140 million, an increase from its prior expectation of approximately $134…View ↗
8-K, filed May 5, 2026
The Company now expects total revenue for the fiscal year ending December 31, 2026 to approximate $882 million, representing approximately…View ↗
Growing. Revenue grew 3.1x in 4 years, from $243.2M in FY2021 to $764.2M in FY2025, about 33% a year.
More planning and navigation software
The older report described an InformatiX platform for spine-care information and EOS imaging; the latest report describes EOS Insight planning software and Valence navigation and robotics, expanding the company's digital tools.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 24, 2026In 2024, we launched EOS Insight™ ("Insight"), a ground-breaking software platform powered by EOS imaging, designed to elevate spine…View ↗
Our EOS imaging system is designed to provide unbiased, high-quality, and calibrated full-body imaging that enables a 3D model of patients’…View ↗
Valence was acquired in 2023. An intra-operative system created by spine experts with deep navigation and robotics know-how, Valence…View ↗
Competes with Medtronic, Johnson & Johnson, Globus Medical, and Zimmer Biomet
10-K for FY2025, filed Feb 24, 2026Both our currently marketed products and any future products we commercialize are subject to fierce competition. We believe that our most…View ↗
Loading...